The AstraZeneca’s Covisheild vaccine against COVID-19 was rolled out in several parts of the world and approved for emergency authorisation in India from 16th January 2021. Real-time post vaccination experience outside the manufacturers vaccine trial is bizarre and not well documented. Knowledge about adverse events following Covisheild vaccine will educate the people, allay their fears, stigma and lower their hesitancy towards vaccination. The aim of our study is to identify the adverse events following Covisheild vaccination in health care workers (HCW’S) at TIMS. Methods: A cross-sectional, observational survey was conducted to study the adverse events following Covisheild immunisation drive among the HCW’S at TIMS from 19th January to 9th March 2021. Results: The acceptance of vaccine among the HCW’S was 60 %. The frequency of incidence of AEFI was significantly less following 2nd dose when compared to 1st dose (p<0.005). Post-vaccination symptoms were more likely reported in women (57.24%) compared to men (56.10%) (p> 0.05). Incidence of AEFI within 30 minutes was significantly higher among females than males (p=0.027). AEFI persisted for a longer duration upto 72hrs among females than males and this difference was statistically significant (p=0.001). Conclusion: Majority of the reported AEFI were, mild, self-limiting, of short duration and none were serious. No hospitalisation was required and nil fatality was observed. This guides the individual to accept the national covid -19 vaccination drive, which is the most crucial step to halt this deadly pandemic. Acceptance and immunisation is crucial to achieve herd immunity to curb this pandemic
